Article Text

other Versions

Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
  1. M Schiff (lmschiff{at}
  1. Denver Arthritis Clinic, United States
    1. M Keiserman (maurokei{at}
    1. Pontificial Catholic University, School of Medicine, Brazil
      1. C Codding (cec{at}
      1. Health Research of Oklahoma, United States
        1. S Songcharoen (suthin{at}
        1. Arthritis & Osteoporosis Center, United States
          1. A Berman (albertoberman{at}
          1. Centro Medico Privado De Reumatologia, Argentina
            1. S Nayiager
            1. St Augustine's Hospital, South Africa
              1. C Saldate (saldate{at}
              1. Centro de Investigacion del Noroeste, Mexico
                1. T Li ({at}
                1. Bristol-Myers Squibb, United States
                  1. R Aranda (richard.aranda{at}
                  1. Bristol-Myers Squibb, United States
                    1. J-C Becker (jeanclaude.becker{at}
                    1. Bristol-Myers Squibb, United States
                      1. C Lin (carol.lin{at}
                      1. Bristol-Myers Squibb, United States
                        1. P LN Cornet (patricia.cornet{at}
                        1. Bristol-Myes Squibb, United States
                          1. M Dougados (maxime.dougados{at}
                          1. Paris-Descartes University; Cochin Hospital, France


                            Objectives: This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo. The primary objective of this study was to evaluate of a mean change from baseline in DAS28 (ESR) for the abatacept versus placebo groups at Day 197.

                            Methods: Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) were randomized 3:3:2 to abatacept (~10 mg/kg every 4 weeks [n=156]), infliximab (3 mg/kg every 8 weeks [n=165]), or placebo (every 4 weeks [n=110]) and background MTX. Safety and efficacy were assessed throughout the study.

                            Results: Similar patient demographics and clinical characteristics were present at baseline between groups, with mean scores of ~1.7 for HAQ-DI and 6.8 for DAS28 (ESR). At 6 months, mean changes in DAS28 (ESR) were significantly greater for abatacept vs placebo (–2.53 vs –1.48, p<0.001) and infliximab vs placebo (–2.25 vs –1.48, p<0.001). For abatacept vs infliximab treatment at Day 365, reductions in the DAS28 (ESR) were –2.88 vs –2.25. At Day 365, the following response rates were observed for abatacept and infliximab, respectively: ACR 20: 72.4 and 55.8%; ACR 50: 45.5 and 36.4%; ACR 70: 26.3 and 20.6%; LDAS: 35.3 and 22.4%; DAS28-defined remission: 18.7 and 12.2%; good EULAR: 32.0 and 18.5%; and HAQ-DI: 57.7 and 52.7%. Mean changes in PCS were 9.5 and 7.6, and MCS were 6.0 and 4.0, for abatacept and infliximab, respectively. Through 1 year, adverse events (AEs) (89.1 vs 93.3%), serious AEs (SAEs) (9.6 vs 18.2%), serious infections (1.9 vs 8.5%) and discontinuations due to both AEs (3.2 vs 7.3%) and SAEs (2.6 vs 3.6%) were lower with abatacept than infliximab.

                            Conclusions: In this study, abatacept and infliximab (3 mg/kg every 8 weeks) demonstrated similar efficacy. Overall, abatacept had a relatively more acceptable safety and tolerability profile, with fewer SAEs, serious infections, acute infusional events and discontinuations due to AEs than the infliximab group.

                            • abatacept
                            • infliximab
                            • rheumatoid arthritis

                            Statistics from

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.